Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.
Pancreatic adenocarcinoma remains a most deadly malignancy, with an overall 5-year survival of 5%. A subset of patients will be diagnosed with potentially resectable disease, and while complete surgical resection provides the only chance at cure, data from trials of postoperative chemoradiation and/or chemotherapy demonstrate a modest survival advantage over those patients who undergo resection alone. As such, most practitioners believe that completion of multimodality therapy is the optimal treatment. However, the sequence of surgery, chemotherapy and radiation therapy is frequently debated, as patients may benefit from a neoadjuvant approach by initiating chemotherapy and/or chemoradiation prior to resection. Here we review the rationale for neoadjuvant therapy, which includes a higher rate of completion of multimodality therapy, minimizing the risk of unnecessary surgical resection for patients who develop early metastatic disease, improved surgical outcomes and the potential for longer overall survival. However, there are no prospective, randomized studies of the neoadjuvant approach compared to a surgery-first strategy; the established and ongoing investigations of neoadjuvant therapy for pancreatic cancer are discussed in detail. Lastly, as the future of therapeutic regimens is likely to entail patient-specific genetic and molecular analyses, and the treatment that is best applied based on those data, a review of clinically relevant biomarkers in pancreatic cancer is also presented.
Jeffrey M Sutton, Daniel E Abbott, Department of Surgery, Division of Surgical Oncology, University of Cincinnati Medical Center, Cincinnati, OH 45219, United States.
Jeffrey M
JM
Sutton
Jeffrey M Sutton, Daniel E Abbott, Department of Surgery, Division of Surgical Oncology, University of Cincinnati Medical Center, Cincinnati, OH 45219, United States.
Daniel E
DE
Abbott
D000230:Adenocarcinoma / Q000266:history / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant / Q000266:history / Q000639:trends; D017024:Chemotherapy, Adjuvant; D004059:Diffusion of Innovation; D005544:Forecasting; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D020360:Neoadjuvant Therapy / Q000266:history / Q000639:trends; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000266:history / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome
Biomarkers; Chemoradiation; Chemotherapy; Neoadjuvant therapy; Pancreatic cancer